Distribution of Prognostic Scores at the Time of Diagnosis

Revised International Prognostic Scoring System (IPSS-R) score distribution

Using the IPSS-R at time of diagnosis (evaluated in the diagnosed patient cohort; N=7012) for the patient population included in the IPSS-R analysis, the majority of patients with myelodysplastic syndromes (MDS) may fall into very low, low, and intermediate risk categories.1

Distribution of patients with MDS by IPSS-R risk status (N=7012)1

  • 77% of patients were of lower-risk status (very low, low, and intermediate prognostic subgroups)1
  • 23% of patients were higher risk (high and very high prognostic subgroups)1
  • 77% of patients were of lower-risk status (very low, low, and intermediate prognostic subgroups)1
  • 23% of patients were higher risk (high and very high prognostic subgroups)1

IPSS-R, Revised International Prognostic Scoring System.

Median survival by IPSS-R prognostic score

Median survival for patients with very low, low, and intermediate IPSS-R scores ranged from 3 years to more than 8 years.1

Survival duration for all patients (N=7012) within the 5 prognostic groups of the IPSS-R1


CI, confidence interval.

Median time to acute myeloid leukemia (AML) progression by IPSS-R score

Time to AML evolution (N=6485) for patients within the 5 prognostic groups of the IPSS-R.1

Very Low Low Intermediate High Very High
AML/25%,a Years
(95% CI)
NR (14.5-NR) 10.8 (9.2-NR) 3.2 (2.8-4.4) 1.4 (1.1-1.7) 0.7 (0.7-0.9)
Prognostic Group AML/25%,a Years
(95% CI)
Very Low NR (14.5-NR)
Low 10.8 (9.2-NR)
Intermediate 3.2 (2.8-4.4)
High 1.4 (1.1-1.7)
Very High 0.7 (0.7-0.9)

aMedian time to 25% AML evolution.

AML, acute myeloid leukemia; CI, confidence interval; NR, not reached.

Reference: 1. Greenberg PL, Tuechler H, Schanz J, et al. Revised International Prognostic Scoring System for myelodysplastic syndromes. Blood. 2012;120(12):2454-2465.